Extend Biosciences

Extend Biosciences has developed a novel platform technology (D-VITylation®) that significantly improves the pharmacokinetic properties of peptides and proteins. The company has demonstrated that the attachment of a small vitamin D-based molecule protects the conjugated peptide or protein from renal clearance by virtue of reversible binding to the serum-circulating vitamin D-binding protein without compromising bioactivity.

The Company’s lead D-VITylated drug candidate, EXT608, targets the rare disease Hypoparathyroidism (HPT) and is being developed as a subcutaneously self-administered once-weekly dosing regimen for improved patient compliance and superior efficacy.